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Abstract
Aims/hypothesis Intronic single nucleotide polymorphisms
within the transcription factor 7-like 2 (TCF7L2) gene are
associated with risk of type 2 diabetes. It is widely
hypothesised that the predisposing variation is involved in
cis-regulation of TCF7L2 activity. The aim of this study
was to seek evidence for the existence of novel TCF7L2
isoforms encoded within the type 2 diabetes-associated
genomic region.
Methods We searched expressed sequence tag (EST) data-
bases for novel TCF7L2 transcripts and sought to validate
the function and integrity of any isoforms found using a
combination of RT-PCR, western blotting and reporter gene
techniques.
Results Analysis of EST databases suggested the presence
of an alternative polyadenylation site located in intron 4 of
TCF7L2. We used 3′ rapid amplification of cDNA ends and
real-time PCR to validate the integrity of this polyadeny-
lation signal and show its wide use across human tissues.
Western blotting results are consistent with the use of this
polyadenylation signal to generate novel protein isoforms.
The alternative polyadenylation signal results in the
production of isoforms that retain the β-catenin binding
domain but do not possess the high-mobility group box
DNA-binding domain. Promoter–reporter gene assays
suggest that these isoforms inhibit TCF7L2-dependent
target genes by sequestering β-catenin.
Conclusions/interpretation We have identified a novel
polyadenylation signal within TCF7L2 that can result in
the production of isoforms that act to repress TCF/LEF-
dependent target genes. These findings may provide new
insights into the association of TCF7L2 with susceptibility
to type 2 diabetes.
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Abbreviations
ASP Adaptor-specific primer
EST Expressed sequence tag
GSP Gene-specific primer
LD Linkage disequilibrium
mAb Monoclonal antibody
pAb Polyclonal antibody
RACE Rapid amplification of cDNA ends
SNP Single nucleotide polymorphism
TCF/LEF T cell factor/lymphoid-enhancer factor
Introduction
Studies have shown single nucleotide polymorphism (SNPs)
in TCF7L2 to be consistently associated with a risk of type
2 diabetes [1]. Despite evidence that attenuation of
transcription factor 7-like 2 (TCF7L2) activity mimics the
phenotypic effects seen in human carriers of alleles
associated with risk [2–4], no protein-coding variation has
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been found to explain the association. Therefore it is
likely that the association acts via an effect on TCF7L2
transcription, splicing or polyadenylation.
TCF7L2 belongs to the T cell factor/lymphoid-
enhancer factor (TCF/LEF) family of transcription
factors that use extensive alternative splicing to generate
isoforms with unique temporal/spatial profiles and gene/
context-dependent transactivation capabilities [5, 6].
Given that each TCF/LEF member binds to the same co-
activator (β-catenin) and consensus DNA sequence, the
molecular diversity generated by splicing may help to
explain the lack of functional redundancy within this
family.
Interestingly, most of the post-transcriptional events
reported for TCF7L2 involve 3′ exons, which do not lie
within the region associated with type 2 diabetes. To
explain the link, we hypothesised that there might be as
yet undiscovered isoforms transcribed within the associated
linkage disequilibrium (LD) block.
Methods
Samples and mRNA analysis Human tissue RNA from
individual donors and pools of donors was purchased from
Ambion (Austin, TX, USA) and AMS Biotechnology
(Abingdon, UK). No individual’s RNA was present in
more than one tissue sample. Snap-frozen islets were
bought from the National Disease Research Interchange
(Philadelphia, PA, USA), and RNA extracted (mirVana
miRNA isolation kit; Ambion).
All RNA was DNase-treated (TURBO DNA-free kit;
Ambion). For 3′ rapid amplification of cDNA ends
(RACE), RNA was reverse-transcribed using an oligo-dT
anchor primer (GCTGTCAACGATACGCTACGTAA
CGGCATGACAGTGT(15)) and amplified by nested PCR
(Advantage 2 PCR Kit; Clontech, Paris, France) using
gene-specific (GSP) and adaptor-specific (ASP) primers
(GSP1_GCACACATTGTCGTAAGTAACCTCCCA,
ASP 1 _GCTGTCAACGATACGCTACGTAAC ,
GSP2_GTAAGTAACCTCCCAGAGATGATGGCT,
ASP2_CGCTACGTAACGGCATGACAGTG). PCR
methods were as detailed in the manufacturers’ instruc-
tions. Second-round product was resolved by agarose gel
electrophoresis and, owing to the presence of one band,
sequenced using the ABI 3730 DNA sequencer (Applied
Biosystems, Foster City, CA, USA).
To quantify polyadenylation site usage in tissues, RNA
was reverse-transcribed using the SuperScript III First-
Strand Synthesis System (Invitrogen, Paisley, UK). TaqMan
probes (Applied Biosystems) were designed to amplify the
isoform-specific coding region and an intronic region
downstream of the alternative cleavage site. Inventoried
TaqMan probes (Applied Biosystems) were used to measure
the expression of the housekeeping genes GAPDH, B2M
and GUSB.
All quantitative PCR reactions were run on an ABI
7900HT using TaqMan Universal PCR Master Mix
(Applied Biosystems). Relative expression was calculated
using the comparative Ct method [7]. The GeNorm [8]
algorithm was used to normalise expression of full-length
TCF7L2.
Western blotting Nuclear extracts from human adult
pancreas, small intestine (AMS Biotechnology), HeLa
cells (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
and MIN6 cells (lysed in RIPA buffer) were denatured
and reduced in 2× Laemmli buffer. Extracts were
separated on a 10% polyacrylamide gel and transferred
to PVDF membrane before being blocked in 5% milk for
1 h at 4°C and incubated overnight at 4°C with primary
antibody diluted to 1:1,000 (polyclonal antibody [pAb],
sc-8631; Santa Cruz Biotechnology; monoclonal antibody
[mAb], #2565; Cell Signaling Technology, Danvers, MA,
USA). Horseradish peroxidase-conjugated secondary anti-
body (for pAb, sc-2020; for mAb, sc-2004; Santa Cruz
Biotechnology) was added (1:20,000) for 1 h at room
temperature before chemiluminescent detection using
SuperSignal West Pico Substrate (Pierce, Rockford, IL,
USA). Where appropriate, blots were stripped and
reprobed for fibrillarin (sc-25397; Santa Cruz Biotechnology)
or tubulin (T5168; Sigma Aldrich, St Louis, MO, USA).
In the blocking peptide experiment, membrane was
incubated overnight with blocking peptide (sc-8631P)
and primary pAb.
Cloning and reporter gene assay The coding sequence for
isoforms generated using the alternative polyadenylation
signal was amplified by PCR from human cDNA and
cloned into pIRES2-EGFP (Clontech). This construct is
called Poly(A). Subsequently, D16A Poly(A) was generated
by site-directed mutagenesis (QuikChange II XL Site-
Directed Mutagenesis Kit; Stratagene, La Jolla, CA, USA)
to mutate amino acid residue 16, critical for β-catenin
binding [9]. A vector encoding a constitutively active form
of β-catenin [6] was a gift from A. Hecht (University of
Freiburg, Germany). Mutations and correct insertion into
vectors was verified by sequencing. Plasmids were
introduced into MIN6 cells using Lipofectamine 2000
(Invitrogen). pTOPFLASH, a luciferase construct contain-
ing an ‘optimal’ TCF/LEF promoter with three copies of
the TCF/LEF-binding motif, CCTTTGATC, was a gift
from T. Dale (Cardiff University, UK). To control for
differences in transfection efficiency, pRL-CMV (cyto-
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megalovirus immediate early enhancer/promoter region)
was co-transfected and Renilla luciferase measured. Cells
were cultured for 48 h in complete MIN6 media prior to
assay in a luminometer (Berthold Lumat LB 9507, Bad
Wildbad, Germany) using the Dual-Glo luciferase system
(Promega, Madison, WI, USA).
Results
An alternative polyadenylation signal within intron 4 of
TCF7L2 is widely used in human tissues Using expressed
sequence tag (EST) databases, we searched within the type
2 diabetes-associated LD block for sequences that could be
part of a novel TCF7L2 transcript. ECgene [10] (http://
genome.ewha.ac.kr/ECgene/gbr/; accessed 18 July 2011)
and AceView [11] (www.ncbi.nlm.nih.gov/IEB/Research/
Acembly/; accessed 18 July 2011) provide evidence for
spliced human and mouse transcripts, respectively, contain-
ing sequence extending into intron 4.
We hypothesised that there might be an alternative
polyadenylation signal present, which would result in the
use of an alternative translational stop codon and the
production of isoforms possessing the β-catenin binding
domain but not the HMG (high-mobility group) box DNA-
binding domain. To determine whether an alternative
polyadenylation signal is present in intron 4, we performed
3′ RACE on human pancreas cDNA and found a novel
cleavage site at IVS4+1100. The 3′ end contains consensus
sequences required for 3′ end formation in the correct
spatial requirements (Fig. 1a). Real-time PCR analysis
showed similar levels of truncated transcripts, relative to
TATTTTTATAAA ACCATATTTTGAGTCATCATTTGTGACAATGTCTTCTTTT CTC
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Fig. 1 Identification of an alternative polyadenylation signal within
intron 4 of TCF7L2 widely used in human tissues. a Schematic
depicting the location of the alternative polyadenylation signal within
the human TCF7L2 gene. The dark grey rectangle represents the
isoform-specific coding region, and the light grey rectangle the
isoform-specific 3′ untranslated region, generated by the use of the
novel polyadenylation signal. Cis sequences probably involved in 3′
end formation are detailed with boxes encompassing the polyadeny-
lation sequence and U-rich element. The arrow indicates the cleavage
site. Positions of the amplicons for TaqMan analysis are shown. b The
relative use of the alternative polyadenylation site across a selection of
human tissues involved in the pathogenesis of type 2 diabetes.
Relative expression was determined using custom TaqMan assays that
amplify the isoform-specific coding region and intronic sequences
downstream of the alternative cleavage site. c The relative expression
of full-length TCF7L2 expression across human tissues. Expression
was normalised using the GeNorm algorithm, which selected B2M and
GUSB as the two most stable housekeeping genes of those measured.
All expression values are relative to that of one kidney sample.
Numbers in brackets indicate the number of separate RNA samples on
which expression was measured. Data are presented as the mean and
standard error
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full-length TCF7L2 transcripts, across a number of tissues
involved in the pathogenesis of type 2 diabetes (Fig. 1b).
The production of full-length TCF7L2 transcripts was
highest in pancreas, small intestine and brain, and lowest in
kidney, skeletal muscle and liver (Fig. 1c). These results are
consistent with a previous report examining TCF7L2
expression across human tissues [5].
Existence of isoforms utilising the alternative polyadenylation
signal supported by western blotting Western blot analysis
using two antibodies targeting the N-terminus of TCF7L2,
and nuclear extracts from human adult pancreas, small
intestine and HeLa cells, shows we can detect full-length
isoforms of the expected size (approximately 60 kDa)
(Fig. 2a). The naive molecular mass of isoforms generated
using the alternative polyadenylation signal would be
approximately 20 kDa, and an interaction between the
antibody and a protein of approximately 20 kDa was seen
in all samples. Discrepancies in the number of high
molecular mass bands observed across different samples
may be explained by the presence of isoforms specifically
produced in pancreas [5] and differences in antibody–
antigen interactions between the two antibodies. A blocking
peptide experiment confirmed the specificity of the bands
observed with the pAb. Mass spectrometry could be used to
unequivocally determine the identity of the proteins within
the observed bands.
Effect of overexpression of truncated isoform on
transcriptional activation We next tested the prediction
that these novel isoforms bind to β-catenin but not to DNA,
and hence might act to repress the activity of other TCF7L2
isoforms on their target promoters. In clonal MIN6 beta
cells, transfection of a vector encoding a constitutively active
form of β-catenin was able to transactivate a luciferase
reporter gene downstream of a TCF/LEF promoter. Co-
transfection of β-catenin and the truncated isoform signifi-
cantly reduced luciferase production (empty vector+β-
catenin vs Poly(A)+β-catenin; p=0.003). Co-transfection
of β-catenin and a mutated version of the truncated isoform
(D16A Poly(A)), with reduced affinity for β-catenin, did
not inhibit luciferase production. Western blotting confirms
that both versions of the truncated isoform were produced,
and at a higher level than that seen in control cells
(Fig. 2b). These results suggest that isoforms generated
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Fig. 2 The use of the alternative polyadenylation signal generates
protein isoforms with the ability to inhibit TCF/LEF-dependent
transcription. a TCF7L2 protein production in human adult pancreas,
small intestine and HeLa cells using a pAb. The specificity of the
antibody–protein interaction at 20 kDa is proven by a blocking
peptide (+BP) experiment and use of a monoclonal TCF7L2 antibody
(mAb) predicted to bind to the truncated isoform. Fibrillarin was used
as a loading control. b An isoform generated by the use of the
alternative polyadenylation signal inhibits TCF/LEF-dependent target
genes by sequestering β-catenin. MIN6 cells were co-transfected with
firefly and Renilla luciferase reporter genes and expression vectors as
indicated. The β-catenin (β-cat) construct encodes a constitutively
active form of this protein. Firefly luciferase production was
driven by a promoter containing three copies of the consensus
TCF/LEF-binding motif, CCTTTGATC. Renilla luciferase was
measured to correct for differences in transfection efficiency.
Reporter gene activities were determined 48 h post-transfection.
Bars represent relative luciferase activities compared with control
transfected with empty vector and β-catenin. Mean values and
standard deviations from five independent experiments are given.
Western blotting was performed to determine TCF7L2 and tubulin
protein production in transfected samples. **p<0.01
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by the use of the alternative polyadenylation signal
inhibit TCF/LEF-dependent transcription by a mechanism
involving β-catenin sequestration.
Discussion
In this paper, we have identified a novel polyadenylation
signal within TCF7L2 that results in the production of
isoforms that may inhibit the activity of full-length TCF7L2
isoforms. Given the context-dependent nature of TCF7L2
isoforms, it would be unwise to extrapolate this effect to all
TCF/LEF-dependent genes in vivo, or to exclude alterna-
tive roles for this isoform in regulating gene expression.
Indeed, a similarly truncated TCF7L2 isoform in mouse has
been shown to inhibit TCF/LEF-dependent target genes but
potentiate the co-activation of non-TCF/LEF-dependent
target genes by β-catenin [12].
Phenotypic characterisation suggests that SNPs in TCF7L2
modulate the risk of type 2 diabetes, primarily through an
effect on insulin secretion [3]. It has been shown, specifically
in islets, that the risk-associated T allele of the diabetes-
associated SNP, rs7903146, exists in a more open chromatin
state than the opposing C allele, and that the T allele
possesses greater enhancer activity selectively in islet beta
cell lines [13, 14]. This increased enhancer effect for the risk-
associated allele is somewhat at odds with the results from
RNA interference experiments conducted in beta cells, which
suggest that a loss of TCF7L2 function causes a predispo-
sition to diabetes [2, 4]. To reconcile the differences in
experimental findings, it is possible that the T allele enhances
the production of a repressive TCF7L2 isoform, such as the
one described in this study. A large number of human islet
samples would likely be needed to test this hypothesis.
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